Future of Drug Discovery

This episode is a discussion between ⁠Rahmad Akbar, Senior Data Scientist in Antibody Design at Novo Nordisk and Murat Tunaboylu⁠, Co-Founder and CEO of Antiverse⁠. You will learn: The impact antibody design has on the world. How AI is helping to push antibody design forward, bringing new therapies to patients. What will antibody design look like in the future? Rahmad's LinkedIn page. Rahmad's Personal Website. Antibody Origami: Here. Rahmad's Previous and Existing Team: Victor Greiff (GreiffLab). Paolo Marcatili, Ludovica Beltrame, Rasmus Høiberg-Nielsen (Antibody Design at Novo Nordisk). "And a big shout out to budding antibody designers (scientists) everywhere especially from my home country Indonesia!' - Rahmad. Be sure to like, rate and review the podcast if you enjoyed this episode! Visit our website: https://www.antiverse.io/ Follow us: LinkedIn: ⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/antiverse/⁠⁠⁠⁠⁠⁠⁠ X: ⁠⁠⁠⁠⁠⁠⁠https://twitter.com/AntiverseHQ⁠⁠

In this episode, we speak with ⁠⁠Björn Schimmöller, Co-Founder and CEO of iuvantium, a synthetic immunobiology company developing new modalities for the next generation of immunotherapies.Host: ⁠⁠Murat Tunaboylu⁠⁠, Co-Founder and CEO of Antiverse.You will learn: The founding journey of iuvantium from Oxford University. How Iuvantium is enhancing immune system efficiency and reducing clinical trial uncertainty using inorganic chemistry. ‘Decoding’ the immune system and how personalised medicine may lead to the next leaps in immunotherapy.Things mentioned: ⁠⁠AstraZeneca COVID-19 vaccine John Austyn - CSO and Co-Founder of Iuvantium Ralph Steinman Farooq Khan - AI Architect at Iuvantium ‘Artificial Lymph Nodes’ Simon Sinek - The Infinite GameAdditional Materials: ⁠Contact iuvantium: info@iuvantium.com⁠⁠ iuvantium website: https://iuvantium.com/ iuvantium LinkedIn: https://www.linkedin.com/company/iuvantium/ First time hearing about Antiverse?Antiverse is an artificial intelligence-driven techbio company that specialises in antibody design against difficult-to-drug targets, including G-protein coupled receptors (GPCRs) and ion channels. Headquartered in Cardiff, UK and with offices in Boston, MA, Antiverse combines state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics. With a primary focus on establishing long-term partnerships, Antiverse has collaborated with two top 20 global pharmaceutical companies. In addition, they are developing a strong internal pipeline of antibodies against several challenging drug targets across various indications.For more information, please visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.antiverse.io⁠⁠Never miss a future event!We'll notify you when a new event is scheduled. Fill out ⁠⁠⁠⁠⁠⁠this form⁠⁠⁠⁠⁠⁠ to sign up for marketing communications from Antiverse. We post about upcoming events on LinkedIn and Twitter.LinkedIn: ⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/antiverse/⁠⁠⁠⁠⁠⁠X: ⁠⁠⁠⁠⁠⁠https://twitter.com/AntiverseHQ⁠⁠

In this talk, Murat speaks with Ming (Tommy) Tang, Director of Computational Biology at Immunitas Therapeutics, an immuno-oncology start-up developing novel therapeutics for patients with cancer. Tommy is a strong leader and communicator in the field of computational biology. He has dedicated his life's work to accelerating cancer research, with prominent expertise in analysing large-scale bulk sequencing data, single-cell and spatial transcriptomic data and epigenetic data.Outside of his career at Immunitas, Tommy is a brilliant science communicator and teacher, with various educational streams, including Twitter, a blog, a GitHub repository, a YouTube channel, a newsletter, as well as authoring his own book, 'From Cell Line To Command Line'. He is passionate about teaching biologists the computational skills essential for modern science. You will learn: How to stay ahead of the curve: developing the data analysis and bioinformatics skills essential to modern research. How Immunitas is developing a discovery engine to aid the fight against cancer and the computational workflows behind it. How to transition from a biologist to a computational biologist. About the shift from academia to industry. About Tommy's inspiring journey. Things mentioned:Link to all Tommy's resources: https://tommytang.bio.link/ Shanghai Jiao Tong University University of Florida MOOC Platforms: Udacity, Coursera, edX Biostars MD Anderson Cancer Center Roel Verhaak Cancer Genome Atlas Project Harvard Faculty of Arts and Sciences Shirley Liu's group at Dana Farber Cancer Immunological Data Commons Mount Sinai Stanford Tommy's Blog: https://divingintogeneticsandgenomics.com/ Immunitas's lead candidate: CD161 / IMT-009 / KORV1 Workflow management systems: SnakeMake, Nextflow... Visgene Matthew Berstein PD-1 Recursion Bridges the Protein and Chemical Space with Massive Protein-Ligand Interaction Predictions Spanning 36 Billion Compounds. Additional Materials: ⁠⁠⁠⁠⁠⁠⁠⁠⁠Watch the recording of the live event! ⁠https://youtu.be/CYa9rDFDaaI First time hearing about Antiverse? Antiverse is an artificial intelligence-driven techbio company that specialises in antibody design against difficult-to-drug targets, including G-protein coupled receptors (GPCRs) and ion channels. Headquartered in Cardiff, UK and with offices in Boston, MA, Antiverse combines state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics. With a main focus on establishing long-term partnerships, Antiverse has collaborated with two top 20 global pharmaceutical companies. In addition, they are developing a strong internal pipeline of antibodies against several challenging drug targets across various indications. For more information, please visit ⁠⁠https://www.antiverse.io⁠⁠ Never miss a future event! We'll notify you when there's a new event scheduled. Fill out ⁠⁠⁠this form⁠⁠⁠ to sign up for marketing communications from Antiverse. We post about upcoming events on LinkedIn and Twitter. LinkedIn: ⁠⁠⁠https://www.linkedin.com/company/antiverse/⁠⁠⁠ X: ⁠⁠⁠https://twitter.com/AntiverseHQ⁠

In this talk, Murat speaks with Abhishek Pandey, Principle Research Scientist and Pharma Discovery Group Lead at AbbVie. Abhishek currently leads RAIDERS, a Pharma Discovery group integrating machine learning across all of AbbVie's working groups to augment drug discovery capabilities. Abhishek's groups work spans cheminformatics, imaging research, multi-omics, as well as the computation behind many of AbbVie's current partnerships and collaborations. We'll be exploring how the machine learning group is transforming the processes across multiple working groups at the pharmaceutical giant, AbbVie. We'll also be unravelling the story of how Abhishek began his pioneering work at AbbVie.You will learn: About Abhishek's strategy for bridging chemistry, biology and computer science expertise to integrate machine learning across AbbVie's pharma discovery processes. About Abhishek's vision for the future of drug discovery, as we explore the pressing needs of the pharmaceutical industry from both a technical and social standpoint.About Abhishek:Abhishek started his career as a software engineer at Toshiba. Following this, Abhishek began his PhD in medical engineering and image processing at the University of Arizona. This led Abhishek to become a core member of the precision medicine AI team at Tempus, developing ways to improve cancer imaging pipelines to help oncologists detect cancers more efficiently. Abhishek then joined AbbVie, where he founded the machine learning / deep learning team - the influence of which has expanded across the entire company. Things mentioned: Abhishek Pandey⁠, Principle Research Scientist and Pharma Discovery Group Lead at ⁠AbbVie⁠. RAIDERS: Pharma Discovery and Developmental Sciences team at AbbVie. Google Meta Toshiba Tempus Labs (now Tempus). PADME (Protein And Drug Molecule interaction prEdiction), a framework based on Deep Neural Networks, to predict real-valued interaction strength between compounds and proteins. NeurIPS Conference (Conference on Neural Information Processing Systems) InSitro FacebookAdditional Materials: ⁠⁠⁠⁠⁠Watch the recording of the live event! ⁠https://www.youtube.com/watch?v=F9kADawRPOsFirst time hearing about Antiverse? Antiverse is an artificial intelligence-driven techbio company that specialises in antibody design against difficult-to-drug targets, including G-protein coupled receptors (GPCRs) and ion channels. Headquartered in Cardiff, UK and with offices in Boston, MA, Antiverse combines state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics. With a main focus on establishing long-term partnerships, Antiverse has collaborated with two top 20 global pharmaceutical companies. In addition, they are developing a strong internal pipeline of antibodies against several challenging drug targets across various indications. For more information, please visit https://www.antiverse.io Never miss a future event! We'll notify you when there's a new event scheduled. Fill out ⁠this form⁠ to sign up for marketing communications from Antiverse. We post about upcoming events on LinkedIn and Twitter. LinkedIn: ⁠https://www.linkedin.com/company/antiverse/⁠ Twitter (x.com) : ⁠https://twitter.com/AntiverseHQ

In this episode, we speak with Alan Nafiev, Co-Founder and CEO of ‘RECEPTOR.AI’, an Artificial Intelligence (AI)-drug discovery company focused on screening small drug molecule candidates against difficult-to-drug targets.Alan gives some key insights into the history of Receptor AI, the company's successes and obstacles, and how Receptor AIs 'software as a service' (SaaS) and services are streamlining the drug discovery process for pharmaceutical and biotech companies. He also discusses how Receptor AIs technology can automate and customise drug discovery pipelines.To conclude, Alan explains Receptor AIs plans for 2023 - branching into membranotropic drug discovery for cancer and cardiovascular diseases, through designing drugs against unique membrane environments. Things mentioned:Sergii Starosyla, Co-Founder and CTO of Receptor AI.Semen Yesylevskyy, Co-Founder and CSO of Receptor AI. Enamine, a partner to Receptor AI. Additional Materials: SIRT1 Case StudyBRD4 Case StudySelectivity BenchmarkPlatform Benchmarks and TestsBifunctional Protein DegradarsProduct DeckEnd-to-End Drug Candidate Design via Active LearningAbout Antiverse:Antiverse was co-founded in 2017 with the goal of engineering the future of drug discovery to change people's lives. Based in Cardiff, Antiverse combines machine learning and phage display techniques to model antibody-antigen interactions. The current version of the platform uses next-generation sequencing and AI to design diverse antibody candidates for any given target. The technology is being developed to enable the discovery of biologics for difficult-to-drug targets associated with cancer, heart, and lung diseases.

Future of Drug Discovery Episode #3In this session, Murat talks with Konrad Krawczyk, Assistant Professor SDU and Founder of NaturalAntibody. We will be covering Mr Natural Antibody's views on developing and using bioinformatics tools to analyse and discover biologics.Other topics in this episode:- Changing role of bioinformatics from assisting to being the main driver in biologics discovery- 99% of the job is to get quality data, 1% is computational methods- Collecting data from Patents, Scientific Publications, NGS, Therapeutics from FDA- Developing models for binding prediction and biophysical properties- Predictions of binding and developability, database, tool access, and expertise- Interpretability of ML modelsAntiverse - Engineering the future of drug discovery - https://www.antiverse.io/